Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Plausible Mechanism Draft Guidance
-
Stakeholder Letter Opposing the Patent Eligibility Restoration Act (PERA)
-
Sign-on Letter to Evicore Regarding Interpretation of NCCN Guidelines
-
Stakeholder Letter Supporting Joint Resolutions to Overturn FDA Rule on LDTs
-
ACMG Response to Senate HELP Committee RFI on Diagnostics Regulation
-
Sign-on Letter Opposing the Patent Eligibility Restoraction Act of 2024
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
ACMG Comments on FDA Proposed Rule for Regulation of LDTs
-
Stakeholder Letter Asking Congress Renew Efforts on CLIA Reform and Urge FDA to Halt LDT Rulemaking
-
Letter to FDA Requesting Extension of Comment Period for Proposed Rule on Regulation of LDTs